BBNX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BBNX is not a good immediate buy right now for a beginner long-term investor with available capital, even though the business is growing. The stock is trading flat-to-slightly down, technicals are weak, and there is no Intellectia buy signal today. Analysts remain constructive overall, but the recent price target cuts show tempered expectations. My direct view: hold off for now rather than buying immediately.
Current price is 10.49, essentially at the pivot of 10.515 and below the previous close. The trend is weak: MACD histogram is negative, RSI at 47.98 is neutral, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5. That setup points to a weak short-term trend and no clear breakout signal. Support sits near 9.749, while resistance is 11.281 and 11.754, so upside needs a cleaner reversal before entry.
Revenue in Q1 2026 grew 56.62% YoY, gross margin improved to 59.5%, and management raised guidance across many key metrics. Analysts generally keep Buy/Overweight ratings, with UBS, Stifel, Piper Sandler, Truist, and Lake Street all still constructive. The company also has differentiated technology in the insulin pump market, which supports long-term growth expectations.
No news catalysts appeared in the past week, so there is no near-term event momentum. Net income worsened to -21.9M and EPS declined to -0.49 despite revenue growth, showing the company is still losing money. Recent analyst price targets were cut materially by several firms, and the stock’s technical trend remains bearish. Hedge funds and insiders are neutral, with no meaningful buying signal from either group.
Latest quarter: Q1 2026. Revenue rose to 27.63M, up 56.62% YoY, which is strong top-line growth. Gross margin expanded to 59.5%, also a positive sign for unit economics. However, net income fell to -21.9M and EPS dropped to -0.49, so profitability remains negative and losses are still substantial even with strong sales growth.
Wall Street is mostly positive but has become more cautious on valuation. Stifel and Piper Sandler both kept bullish ratings while cutting price targets to $20, Truist kept Buy but lowered target to $18, and UBS initiated Buy at $24. The downside is that several targets were reduced sharply from prior levels, showing softer near-term expectations. Overall, pros remain constructive on long-term growth, but their target cuts indicate less enthusiasm about immediate upside.
